Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world.

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B.

Data Brief. 2018 May 1;18:1937-1940. doi: 10.1016/j.dib.2018.04.092. eCollection 2018 Jun.

2.

Body Mass Index impacts the choice of lipid lowering treatment with no correlation to blood cholesterol - findings from 52,916 patients in the Dyslipidemia International Study (DYSIS).

Ferrières J, Lautsch D, Gitt AK, De Ferrari G, Toplak H, Elisaf M, Drexel H, Horack M, Baxter C, Ambegaonkar B, Brudi P, Toth PP.

Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13415. [Epub ahead of print]

PMID:
29888459
3.

Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II.

Yan BP, Chiang FT, Ambegaonkar B, Brudi P, Horack M, Lautsch D, Vyas A, Gitt AK.

Int J Cardiol. 2018 Aug 15;265:1-5. doi: 10.1016/j.ijcard.2018.01.099.

PMID:
29885676
4.

Hitting Hard and Early: A Novel Paradigm for Lipid Lowering in Primary Prevention.

Lautsch D, Gitt AK.

Cardiology. 2018 Jun 6;140(1):68-70. doi: 10.1159/000488972. [Epub ahead of print] No abstract available.

5.

How does the TRS 2°P score relate to real-world patients?

Bonaca MP, De Ferrari GM, Atar D, Bash LD, Lautsch D, Bohula EA, Horack M, Brudi P, Ferrieres J, Gitt AK.

Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):72-74. doi: 10.1093/ehjcvp/pvy004. No abstract available.

6.

CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how?

Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt AK, Stellbrink C, Anker SD, Filippatos G, Gasparini M, Hindricks G, Blomström Lundqvist C, Ponikowski P, Ruschitzka F, Botto GL, Bulava A, Duray G, Israel C, Leclercq C, Margitfalvi P, Cano Ó, Plummer C, Sarigul NU, Sterlinski M, Linde C.

Eur J Heart Fail. 2018 Jun;20(6):1039-1051. doi: 10.1002/ejhf.1142. Epub 2018 Feb 19.

PMID:
29457358
7.

Individualised treatment targets in patients with type-2 diabetes and hypertension.

Schmieder RE, Tschöpe D, Koch C, Ouarrak T, Gitt AK; DIALOGUE study group.

Cardiovasc Diabetol. 2018 Jan 22;17(1):18. doi: 10.1186/s12933-018-0661-8.

8.

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world.

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B.

Data Brief. 2017 Nov 14;16:369-375. doi: 10.1016/j.dib.2017.11.034. eCollection 2018 Feb.

9.

Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B.

Atherosclerosis. 2017 Nov;266:158-166. doi: 10.1016/j.atherosclerosis.2017.08.013. Epub 2017 Aug 21.

PMID:
29028484
10.

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.

Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, Laeis P, Fronk EM, Bramlage P, Cohen AT; PREFER in VTE Scientific Steering Committee.

Thromb Res. 2017 Sep;157:181-188. doi: 10.1016/j.thromres.2017.07.029. Epub 2017 Jul 28.

PMID:
28780343
11.

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.

Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Bramlage P, Agnelli G, Prefer In Vte Scientific Steering Committee And The Prefer In Vte Investigators OBOT.

Thromb Haemost. 2017 Jun 27;117(7):1326-1337. doi: 10.1160/TH16-10-0793. Epub 2017 Apr 13.

PMID:
28405675
12.

Sex Differences in Percutaneous Coronary Intervention-Insights From the Coronary Angiography and PCI Registry of the German Society of Cardiology.

Heer T, Hochadel M, Schmidt K, Mehilli J, Zahn R, Kuck KH, Hamm C, Böhm M, Ertl G, Hoffmeister HM, Sack S, Senges J, Massberg S, Gitt AK, Zeymer U.

J Am Heart Assoc. 2017 Mar 20;6(3). pii: e004972. doi: 10.1161/JAHA.116.004972. Erratum in: J Am Heart Assoc. 2017 Sep 6;6(9):.

13.

Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.

Ferrières J, Rouyer MV, Lautsch D, Ashton V, Ambegaonkar BM, Brudi P, Gitt AK; Dyslipidemia International Study (DYSIS) II France Study Group.

Arch Cardiovasc Dis. 2017 Mar;110(3):167-178. doi: 10.1016/j.acvd.2016.11.004. Epub 2017 Feb 13.

14.

Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world.

Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B.

Data Brief. 2016 Sep 29;9:616-620. eCollection 2016 Dec.

15.

Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.

Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B.

Atherosclerosis. 2016 Dec;255:200-209. doi: 10.1016/j.atherosclerosis.2016.09.004. Epub 2016 Sep 9.

PMID:
27667299
16.

Improvement in achievement of lipid targets in France: Comparison of data from coronary patients in the DYSIS and DYSIS II studies.

Ferrières J, Rouyer MV, Lautsch D, Ambegaonkar BM, Horack M, Brudi P, Gitt AK; Dyslipidemia International Study (DYSIS) and DYSIS II Study Group.

Int J Cardiol. 2016 Nov 1;222:793-794. doi: 10.1016/j.ijcard.2016.08.084. Epub 2016 Aug 5. No abstract available.

PMID:
27521563
17.

Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice.

Catapano AL, Lautsch D, Tokgözoglu L, Ferrieres J, Horack M, Farnier M, Toth PP, Brudi P, Tomassini JE, Ambegaonkar B, Gitt AK.

Atherosclerosis. 2016 Sep;252:1-8. doi: 10.1016/j.atherosclerosis.2016.07.007. Epub 2016 Jul 14.

18.

[Hypercholesterolemia - Where are we today? Where are we going?].

Gitt AK, Zahn R.

Herz. 2016 Aug;41(5):413-20. doi: 10.1007/s00059-016-4457-x. Epub 2016 Jul 13. Review. German.

PMID:
27412663
19.

[Modern Lipid therapy today and tomorrow: anti-PCSK9 : A magic bullet concept following Paul Ehrlich].

Erbel R, Gitt AK.

Herz. 2016 Jun;41(4):271-2. doi: 10.1007/s00059-016-4442-4. German. No abstract available.

PMID:
27241696
20.

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry.

Gitt AK, Bramlage P, Potthoff SA, Baumgart P, Mahfoud F, Buhck H, Ehmen M, Ouarrak T, Senges J, Schmieder RE; EARLY Registry Group.

BMC Cardiovasc Disord. 2016 Mar 8;16:56. doi: 10.1186/s12872-016-0222-6.

Supplemental Content

Support Center